Archer Daniels Midland Co., of Decatur, Ill., was awarded U.S. Patent No. 6,399,072 titled "Method of Preparing and Using Isoflavones for the Treatment of Alcoholism." The company also was granted U.S. Patent No. 6,391,310 titled "Method of Preparing and Using Isoflavones for the Treatment of Neurological Symptoms."
Cepheid Inc., of Sunnyvale, Calif., was issued U.S. Patent No. 6,440,725 covering apparatus and methods for the capture of cells and microorganisms on a filter or membrane and the extraction, purification, concentration and elution of their nucleic acids in a fluidic cartridge.
Cyclis Pharmaceuticals Inc., of Norwood, Mass., was issued a notice of allowance for a patent relating to CO-501, the company's lead compound for the treatment of solid tumors. The company said CO-501 represents a new class of antitumor agents based on Cyclis' activated checkpoint therapy platform.
Diversa Corp., of San Diego, was granted U.S. Patent No. 6,440,668 titled "Method of DNA Shuffling with Polynucleotides Produced by Blocking or Interrupting a Synthesis or Amplification Process."
Euroscreen SA, of Brussels, Belgium, was issued U.S. Patent No. 6,448,375 covering a protein containing a specific portion of CCR5 and therefore the full-length wild-type amino acid sequence of CCR5. The patent also discloses the complete description of the pharmacology of the receptor.
GeneMax Corp., of Blaine, Wash., was granted a U.S. patent for the use of TAP-1 (transporters associated with antigen processing) as an immunotherapy against all cancers. The patent is titled "Method of Enhancing Expression of MHC Class I Molecules Bearing Endogenous Peptides."
Generex Biotechnology Corp., of Toronto, was awarded a U.S. patent containing claims to its method of administering insulin to the buccal mucosa by spraying, using a metered-dose spray device.
Geron Corp., of Menlo Park, Calif., was issued U.S. Patent No. 6,440,735 relating to telomerase-based cancer immunotherapy.
Immune Network Ltd., of Vancouver, British Columbia, received a notice of allowance from the U.S. Patent and Trademark Office for each of two patents related to the company's 1F7 technology. The patents, when issued, will cover Immune Network's anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease.
Immuno-Designed Molecules SA, of Paris, was awarded a U.S. patent related to blood monocyte-derived antigen-presenting cells, which have the characteristics of mature dendritic cells.
Isolagen Inc., of Houston, was issued U.S. Patent No. 6,432,710 titled "Compositions for Regenerating Tissue that has Deteriorated and Methods for Using Such Compounds" related to the treatment of periodontal defects.
Odyssey Pharmaceuticals Inc., of San Ramon, Calif., was issued U.S. Patent No. 6,428,951 titled "Protein Fragment Complementation Assays for the Detection of Biological or Drug Interactions."
Peplin Biotech Ltd., of Brisbane, Australia, was granted a U.S. patent for the topical treatment of skin cancer using its compounds. The patent covers the treatment of precancerous actinic keratosis, basal cell carcinoma and squamous cell carcinoma. Although melanoma and Merkel cell carcinoma also are covered by the patent, the company said it intends to address those diseases with forms of the drug more suitable for systemic, rather than topical, delivery.